Amneal Pharmaceuticals, Inc. (AMRX)

USD 7.69

(-4.71%)

Net Income Summary of Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals, Inc.'s latest annual net income in 2023 was -83.99 Million USD , up 67.03% from previous year.
Amneal Pharmaceuticals, Inc.'s latest quarterly net income in 2024 Q1 was -91.64 Million USD , up 7.1% from previous quarter.
Amneal Pharmaceuticals, Inc. reported an annual net income of -254.78 Million USD in 2022, down -1363.21% from previous year.
Amneal Pharmaceuticals, Inc. reported an annual net income of 20.17 Million USD in 2021, down -70.59% from previous year.
Amneal Pharmaceuticals, Inc. reported a quarterly net income of 5.99 Million USD for 2024 Q2, up 106.54% from previous quarter.
Amneal Pharmaceuticals, Inc. reported a quarterly net income of -83.99 Million USD for 2023 FY, up 67.03% from previous quarter.

Annual Net Income Chart of Amneal Pharmaceuticals, Inc. (2023 - 2014)

Historical Annual Net Income of Amneal Pharmaceuticals, Inc. (2023 - 2014)

Year	Net Income	Net Income Growth
2023	-83.99 Million USD	67.03%
2022	-254.78 Million USD	-1363.21%
2021	20.17 Million USD	-70.59%
2020	68.57 Million USD	111.36%
2019	-603.57 Million USD	-255.62%
2018	-169.72 Million USD	-201.24%
2017	167.64 Million USD	-19.16%
2016	207.37 Million USD	22.38%
2015	169.45 Million USD	-4.23%
2014	176.92 Million USD	0.0%

Year	Net Income	Net Income Growth
2024 Q1	-91.64 Million USD	7.1%
2024 Q2	5.99 Million USD	106.54%
2023 FY	-83.99 Million USD	67.03%
2023 Q4	-98.64 Million USD	-1118.89%
2023 Q1	-10.09 Million USD	-72.31%
2023 Q3	9.68 Million USD	-18.75%
2023 Q2	11.91 Million USD	218.06%
2022 Q1	-6.46 Million USD	-1.3%
2022 FY	-254.78 Million USD	-1363.21%
2022 Q4	-5.85 Million USD	-145.1%
2022 Q3	-2.39 Million USD	98.02%
2022 Q2	-120.8 Million USD	-1770.09%
2021 Q3	-4.23 Million USD	-129.16%
2021 Q4	-6.37 Million USD	-50.51%
2021 Q2	14.53 Million USD	116.7%
2021 Q1	6.7 Million USD	320.81%
2021 FY	20.17 Million USD	-70.59%
2020 Q2	-11.99 Million USD	-110.43%
2020 Q4	-3.03 Million USD	66.16%
2020 FY	68.57 Million USD	111.36%
2020 Q3	-8.97 Million USD	25.18%
2020 Q1	115.06 Million USD	458.15%
2019 Q2	-16.9 Million USD	64.7%
2019 Q4	-32.12 Million USD	87.88%
2019 FY	-603.57 Million USD	-255.62%
2019 Q1	-47.88 Million USD	-446.09%
2019 Q3	-265 Million USD	-1467.9%
2018 Q2	-219.44 Million USD	-525.82%
2018 FY	-169.72 Million USD	-201.24%
2018 Q4	-8.76 Million USD	-226.12%
2018 Q3	6.95 Million USD	103.17%
2018 Q1	51.53 Million USD	-16.3%
2017 FY	167.64 Million USD	-19.16%
2017 Q1	42.26 Million USD	-21.59%
2017 Q2	37.44 Million USD	-11.39%
2017 Q3	26.78 Million USD	-28.48%
2017 Q4	61.56 Million USD	129.91%
2016 Q4	53.89 Million USD	0.0%
2016 FY	207.37 Million USD	22.38%
2015 FY	169.45 Million USD	-4.23%
2014 FY	176.92 Million USD	0.0%

Peer Net Income Comparison of Amneal Pharmaceuticals, Inc.

Name	Net Income	Net Income Difference
Bausch Health Companies Inc.	-592 Million USD	85.812%
Catalent, Inc.	-1.04 Billion USD	91.947%
Emergent BioSolutions Inc.	-760.5 Million USD	88.956%
Elanco Animal Health Incorporated	-1.23 Billion USD	93.177%
Perrigo Company plc	-12.7 Million USD	-561.362%
Teva Pharmaceutical Industries Limited	-559 Million USD	84.974%
Zoetis Inc.	2.34 Billion USD	103.583%